Silver

KENGREAL (cangrelor) is a product of Chiesi USA, Inc.

Chiesi USA is committed to developing and commercializing products that meet the needs of healthcare providers and their patients.

We are also dedicated to investing in research and development initiatives that deliver value-added medical solutions in our current therapeutic areas as well as other therapeutic areas where the need exists.

PP-K-0682 V1.0

Contact:

Mirelle Pinkusovich

mirelle.pinkusovich@chiesi.com

(646) 369-4890

Important Safety Information

KENGREAL® (cangrelor) for Injection is contraindicated in patients with significant active bleeding.

KENGREAL® is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.

Drugs that inhibit platelet P2Y12 function, including KENGREAL®, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREAL® than with clopidogrel. Bleeding complications with KENGREAL® were consistent across a variety of clinically important subgroups. Once KENGREAL® is discontinued, there is no antiplatelet effect after an hour.

The most common adverse reaction is bleeding.

Indication

KENGREAL® (cangrelor) for Injection is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.